Opendata, web and dolomites

BabyLux

Launching the First Non-Invasive Brain-Monitoring System for the Early Detection and Management of Encephalopathy In Preterm Babies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BabyLux project word cloud

Explore the words cloud of the BabyLux project. It provides you a very rough idea of what is the project "BabyLux" about.

despite    figures    fall    precise    sub    worldwide    extremely    15    oxygen    segments    babylux    alive    unsolved    hearing    hospitals    combining    live    scientific    babies    fact    flow    credibility    failing    solving    decades    weeks    accurate    monitoring    assumptions    autism    premature    brain    risk    manner    lifelong    reaching    commercialization    37    easing    segment    blood    impairments    sold    first    successful    market    tremendously    disorders    damage    solutions    visual    20    invasive    neonates    entrance    2014    maintaining    gain    until    born    stage    techniques    suffering    13    over    business    births    lasting    last    markets    hemophotonics    turnover    care    anyhow    intensive    gestational    neonatal    affordable    carg    units    period    leads    corroborate       deficit    time    cerebral    million    encephalopathies    clinical    artificial    months    compilation    device    model    requesting    photonic    metabolism    smei    nicus    detect    gestation    paralysis    preterm    200m    partial    commercial    community    mixed   

Project "BabyLux" data sheet

The following table provides information about the project.

Coordinator
HEMOPHOTONICS SL 

Organization address
address: AVENIDA CARL FRIEDRICH GAUSS 3 OFICINA 346 MEDITERRANEAN TECHNOLOGY PARK
city: CASTELLDEFELS
postcode: 8860
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.hemophotonics.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2017-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HEMOPHOTONICS SL ES (CASTELLDEFELS) coordinator 50˙000.00

Map

 Project objective

Over the last two decades preterm babies (neonates with less than 37 weeks of gestational period) have rise tremendously reaching 15 million births worldwide in 2014, and the figures are growing. Anyhow, despite we have been successful at maintaining alive premature babies until their live it’s not at risk, we are failing at solving important side-problems. Preterm babies are at high risk of suffering encephalopathies (brain damage) during the artificial gestational stage on the neonatal intensive-care units (NICUs). In fact, about 20% of babies born before 6.5 months gestation experience lasting brain damage. This leads to lifelong disorders such as attention deficit, autism, cerebral paralysis, and hearing or visual impairments. To early detect cerebral damage in a precise manner it’s necessary to provide real time and accurate measures of cerebral oxygen metabolism and blood flow in the brain. This problem remains unsolved since current commercial solutions provide partial measurements or are extremely invasive. BabyLux will be the first device allowing early detect and manage encephalopathies in preterm-babies in a non-invasive and affordable manner by combining two leading photonic techniques. Our product fall within the sub-segment of “monitoring equipment” for NICUs, which is a € 1.200M market growing at a CARG of 6.5%.BabyLux will be sold at a first commercialization stage to pre-clinical markets (research institutions studying brain damage in neonates). We will proceed in such way since to gain credibility among scientific community, easing the entrance to clinical segments. At a second commercialization stage we will approach clinical segments, in particular hospitals with NICUs. This mixed business model will allow HemoPhotonics to achieve a turnover of € 13 M at 5 years after the project compilation. We are requesting a SMEI Phase 1 to further define and corroborate our business assumptions.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BABYLUX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BABYLUX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.1.;H2020-EU.2.3.1.)

Assist (2015)

Telocate ASSIST – Development and marketing of an acoustic solution for localization and navigation of people in buildings using the smartphone

Read More  

Leaf Line (2018)

The First Global Ground Station Network to Fully Exploit Microsatellites Data

Read More  

SOFT (2017)

SOFT, the first camera-based colorectal cancer screening test to detect occult blood in faeces immediately and with no lab analysis.

Read More